Age-associated biomarker profiles of human breast cancer.

[1]  A. Thor,et al.  p21WAF1/CIP1 Expression in breast cancers: associations with p53 and outcome , 2000, Breast Cancer Research and Treatment.

[2]  C. Paul,et al.  Progestogen-only oral contraceptives and risk of breast cancer in New Zealand , 1996, Cancer Causes & Control.

[3]  J. Campisi,et al.  Senescent fibroblasts promote epithelial cell growth and tumorigenesis: A link between cancer and aging , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[4]  D. Kwiatkowski,et al.  Gelsolin as a negative prognostic factor and effector of motility in erbB-2-positive epidermal growth factor receptor-positive breast cancers. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  A. Thor,et al.  Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  de Elisabeth G. E. Vries,et al.  Differentiated thyroid carcinoma in the elderly. , 2001, Critical reviews in oncology/hematology.

[7]  C. Benz,et al.  Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Ronald A. DePinho,et al.  The age of cancer , 2000, Nature.

[9]  E. Leventhal,et al.  Aging, immunity, and cancer. , 2000, Cancer control : journal of the Moffitt Cancer Center.

[10]  C. Benz,et al.  Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Yancik,et al.  Aging and cancer in America. Demographic and epidemiologic perspectives. , 2000, Hematology/oncology clinics of North America.

[12]  J. Campisi.  Cancer, aging and cellular senescence. , 2000, In vivo.

[13]  J. Foekens,et al.  Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Longo,et al.  Aging and cancer: issues of basic and clinical science. , 1997, Journal of the National Cancer Institute.

[15]  G. Martiny-Baron,et al.  Chemiluminescence immunoassay for vascular endothelial growth factor (vascular permeability factor) in tumor-tissue homogenates. , 1996, Clinical chemistry.

[16]  R. Short.  Why we age , 1996, Nature.

[17]  Muss Hb,et al.  Breast cancer in older women. , 1996 .

[18]  Y. Fujiwara.  [Aging and cellular senescence]. , 1995, Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics.

[19]  D. Neuberg,et al.  Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  B. Ames,et al.  Oxidants, antioxidants, and the degenerative diseases of aging. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[21]  J G Klijn,et al.  The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. , 1992, Endocrine reviews.

[22]  A. Goode,et al.  Epidermal growth factor receptor and oestrogen receptors in the non-malignant part of the cancerous breast. , 1989, British Journal of Cancer.

[23]  D. Fabbro,et al.  PREDICTIVE VALUE OF EGF RECEPTOR IN BREAST CANCER , 1988, The Lancet.

[24]  W. McGuire,et al.  Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  C. Reed,et al.  Lead in dringking water. , 1967, Lancet.